Clinical trial
A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients
NCT07532226 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients
- Lead sponsor
- Janssen-Cilag Ltd.
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- April 17, 2026
- Completion date
- December 10, 2029
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.